Report touts savings of drug plan administrators amid merger controversy

The report goes on to caution against several state and federal proposals that would limit the administrators' ability to cut costs. These include: mandating coverage of brand-name drugs, increasing pharmacy reimbursements, restricting the use of mail-service pharmacies and forcing the disclosure of proprietary contract information. 

The report concludes that government limits on PBMs' cost-containment tools could cost $550 billion over a decade.